Clinical trials: Obesity & Overweight
Obesity, Knee Osteoarthritis (OA)
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis.
- Trial name
- AMAZE 5 (NCT07481630)
- Testing
- NNC0487-0111
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Obesity
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
This is a 56-week randomized, open-label, controlled study evaluating the efficacy and safety of the HDM1005 compared to tirzepatide in adults with obesity but without diabetes.
- Trial name
- NCT07521631
- Testing
- HDM1005 dose level 1, HDM1005 dose level 2, HDM1005 dose level 3
- Where
- China
- Volunteers
- 372 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg/m2 or more, or a BMI of 27 kg/m2 or more and at least 1 health problem related to their weight.
- Trial name
- NCT07662122
- Testing
- BI 3034701
- Where
- 54 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Boehringer Ingelheim
Obesity
Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects
The purpose of this study is to evaluate the PK properties of lorcaserin in obese or overweight elderly subjects.
- Trial name
- NCT00828581
- Testing
- lorcaserin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eisai Inc.
Overweight , Obesity
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07791654
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Prader-Willi Syndrome, Obesity
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.
- Trial name
- bestPWS (NCT02179151)
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Zafgen, Inc.
Metabolism and Nutrition Disorder, Obesity
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with…
- Trial name
- NCT03095807
- Testing
- NNC9204-1706 A
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®).
- Trial name
- COURAGE (NCT06299098)
- Testing
- Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab
- Where
- 60 sites in United States, Puerto Rico
- Volunteers
- 1,005 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Obesity
Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects
The purpose of this study is to learn if BMS-646256 can cause weight loss in men and women who are: overweight with high blood pressure or high cholesterol or obese The safety of this treatment will also be studied
- Trial name
- NCT00388609
- Testing
- BMS-646256
- Where
- 10 sites in United States
- Volunteers
- 705 people
- Sponsor
- Bristol-Myers Squibb
Obesity
Dose-Ranging Study of SKF7® for Obesity
This study has been designed as a randomized, double blinded, multi-centric, placebo controlled and phase II dose-ranging study.
- Trial name
- NCT05851599
- Testing
- SKF7® Labisia pumila standardized extract
- Where
- 6 sites in Malaysia
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Medika Natura Sdn Bhd
Obesity, Hyperlipidemia
A Study on Efficacy and Safety of Topiramate in Treatment of Obese Subjects With Dyslipidemia
The purpose of this study is to compare the efficacy and safety of daily topiramate versus placebo for the treatment of obese subjects with dyslipidemia.
- Conditions
- Obesity, Hyperlipidemia, Hypertriglyceridemia
- Trial name
- NCT00231621
- Testing
- topiramate
- Volunteers
- 179 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Obesity and Diabetes Mellitus, Type 2
A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from…
- Trial name
- NCT03586830
- Testing
- JNJ-64565111 Dose Level 1, JNJ-64565111 Dose Level 2, JNJ-64565111 Dose Level 3
- Where
- 27 sites in United States
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Overweight and Obesity
A Study of DA-302168S in Participants With Overweight/Obesity
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese…
- Trial name
- PANDA-1 (NCT07629544)
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.
Obesity
A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)
The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.
- Trial name
- NCT00533598
- Testing
- MK0557
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Obesity
Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region.
- Trial name
- NCT00987298
- Testing
- Visceral fat mass measurement
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Obesity, Metabolic Syndrome
Effects of Telemonitoring Service for Obesity Care
A randomized, open, parallel, multi-center trial to evaluate weight loss efficacy of Smart Care Service in obese patients with metabolic syndrome.
- Trial name
- Smart-OB (NCT01344811)
- Testing
- Telemonitoring, control group
- Where
- 2 sites in South Korea
- Volunteers
- 661 people
- Sponsor
- Chang Hee, Lee
Diabetes, Obesity
A Trial of the Jejunal Diversion Procedure
This is a single site trial to assess metabolic effects in subjects after a Jejunal Diversion procedure was performed.
- Trial name
- NCT02283632
- Testing
- Jejunal Diversion
- Where
- Czechia
- Volunteers
- 15 people
- Sponsor
- Ethicon Endo-Surgery
Overweight or Obesity
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple ascending doses of IBI3032 in participants with…
- Trial name
- NCT07170319
- Testing
- IBI3032
- Where
- China
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.